LBA
QNCX icon

Letko, Brosseau & Associates’s Quince Therapeutics QNCX Stock Holding History

Letko, Brosseau & Associates’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-27
Closed -$502K – 109
2021
Q3 		$502K Sell
27
-20
-43% -$318K 0.01% 93
2021
Q2 		$502K Hold
47
– – 0.01% 95
2021
Q1 		$341K Hold
47
– – ﹤0.01% 94
2020
Q4 		$263K Buy
47
+16
+52% +$142K ﹤0.01% 104
2020
Q3 		$309K Sell
31
-7
-18% -$63.7K ﹤0.01% 94
2020
Q2 		$353K Buy
+38
New +$348K 0.01% 94

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Letko, Brosseau & Associates's QNCX Position: Q4 2021 in Review

Letko, Brosseau & Associates sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 27 shares — an estimated $502K sold.

Letko, Brosseau & Associates first reported a position in QNCX in Q2 2020 and held it in 6 quarters. The position peaked at $502K in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

  • Letko, Brosseau & Associates reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Letko, Brosseau & Associates sold 27 Quince Therapeutics shares in Q4 2021, an estimated $502K.
  • Letko, Brosseau & Associates first reported a position in Quince Therapeutics in Q2 2020 and held it in 6 quarters.
  • Letko, Brosseau & Associates's Quince Therapeutics position peaked at $502K in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Letko, Brosseau & Associates's 13F filing for Q4 2021, filed 9 Feb 2022.